{
    "organizations": [],
    "uuid": "fb8dc4fd98b737cf64ef0ad32a4aba2dbb878cec",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-nabriva-announces-positive-results/brief-nabriva-announces-positive-results-for-pneumonia-treatment-idUSASC0A30J",
    "ord_in_thread": 0,
    "title": "BRIEF-Nabriva Announces Positive Results For Pneumonia Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Nabriva Therapeutics PLC:\n* NABRIVA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ORAL LEFAMULIN FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA\n* NABRIVA THERAPEUTICS PLC - COMPANY PLANS TO FILE A NEW DRUG APPLICATION WITH U.S. FOOD AND DRUG ADMINISTRATION\n* NABRIVA THERAPEUTICS PLC - LEFAMULIN MET ALL FDA AND EMA PRIMARY ENDPOINTS AND WAS SHOWN TO BE GENERALLY WELL TOLERATED\n* NABRIVA THERAPEUTICS PLC - PLANS TO FILE A NEW DRUG APPLICATION WITH U.S. FOOD AND DRUG ADMINISTRATION IN Q4 OF 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-21T20:08:00.000+03:00",
    "crawled": "2018-05-22T19:28:36.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "nabriva",
        "therapeutic",
        "plc",
        "nabriva",
        "therapeutic",
        "announces",
        "positive",
        "topline",
        "result",
        "pivotal",
        "phase",
        "clinical",
        "trial",
        "oral",
        "lefamulin",
        "treatment",
        "bacterial",
        "pneumonia",
        "nabriva",
        "therapeutic",
        "plc",
        "company",
        "plan",
        "file",
        "new",
        "drug",
        "application",
        "food",
        "drug",
        "administration",
        "nabriva",
        "therapeutic",
        "plc",
        "lefamulin",
        "met",
        "fda",
        "ema",
        "primary",
        "endpoint",
        "shown",
        "generally",
        "well",
        "tolerated",
        "nabriva",
        "therapeutic",
        "plc",
        "plan",
        "file",
        "new",
        "drug",
        "application",
        "food",
        "drug",
        "administration",
        "q4",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}